Personnel Announcement
Novo Nordisk Pharma Ltd. announced that Yukako Akiyama will be appointed as a Director effective June 1, 2026. Ms. Akiyama will continue to serve as General Manager of the Diabetes & Obesity Sales Division.
📋 Article Processing Timeline
- 📰 Published: June 5, 2026 at 01:00
- 🔍 Collected: June 4, 2026 at 16:21
- 🤖 AI Analyzed: June 6, 2026 at 23:04 (54h 43m after Collected)
Novo Nordisk Pharma Ltd. (President & Representative Director: Keisuke Kotani; Head Office: Chiyoda-ku, Tokyo; hereinafter "Novo Nordisk Pharma") hereby announces the following personnel change.
Executive Personnel Change (Effective June 1, 2026)
Name
New Position
Previous Position
Yukako Akiyama
Director
—
Ms. Yukako Akiyama will continue to serve as General Manager of the Diabetes & Obesity Sales Division.
About Novo Nordisk
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to overcome serious chronic diseases, building on our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs approximately 68,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk Pharma Ltd., the Japanese affiliate, was established in 1980. For more information, please visit our website.
www.novonordisk.co.jp
Executive Personnel Change (Effective June 1, 2026)
Name
New Position
Previous Position
Yukako Akiyama
Director
—
Ms. Yukako Akiyama will continue to serve as General Manager of the Diabetes & Obesity Sales Division.
About Novo Nordisk
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to overcome serious chronic diseases, building on our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs approximately 68,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk Pharma Ltd., the Japanese affiliate, was established in 1980. For more information, please visit our website.
www.novonordisk.co.jp
FAQ
When does this personnel change take effect?
It takes effect on June 1, 2026.
What is Yukako Akiyama's new position?
She will become a Director and continue as General Manager of the Diabetes & Obesity Sales Division.
Which company made this announcement?
Novo Nordisk Pharma Ltd.